Ind-Swift Labs launches anti-allergic drug Fexofenadine in US
Fexofenadine is an AntiHistamine Drug used for the treatment of seasonal allergic rhinitis and Urticaria in US market.
Chandigarh: Ind-Swift Laboratories Limited has recently announced that the Company is all set to commercially launch its key Active Pharmaceutical Ingredient (API) - Fexofenadine.
Fexofenadine is an AntiHistamine Drug used for the treatment of seasonal allergic rhinitis and Urticaria in US market.
The Company has tied up with a reputed generic player in the USA, which had filed the ANDA using the IndSwift Laboratories Limited DMF. The Company has received the commercial orders and the supplies are beginning from the current quarter.
"USA is a significant market for this product. Over 14% of the total turnover of the Company is contributed by the US market. The Company supplies 7-8 products commercially to the US market", the company said in a filing
The Company has been successfully inspected by the USFDA in March 2020 for the sixth time since its inception, without any 483 observations. The Company has also received EIR.
Ind-Swift Laboratories Ltd is a global manufacturer of APIs, Intermediates, and formulations (through group collaboration) headquartered in Chandigarh, India.
Read also: Ind-Swift Labs Gets USFDA EIR For Derabassi API Facility
